23–26 April, 2023 ● Hybrid Meeting

Copyright: Modified and published with permission from https://www.ebmt.org/annual-meeting

Sponsorship Statement: Publication of this supplement is sponsored by the European Society for Blood and Marrow Transplantation.

1998

Induction of alloantigen specific anergy does not impair cytolytic activity of leukaemia reactive human T-cells

P. Comolie, F. Locatelli, D. Montagna, V. Calcaterra, A. Moretta, G. Giorgiani, F. Bonetti, M. Zecca, R. Maccario (Pavia, I)

1999

First results of the autologous transplantation after serum-free retroviral gene marking of chemotherapy mobilised PBSC in chronic myeloid leukaemia

C. von Kalle, H. Glimm, S. Klingenberg, M. Schmidt, C. Waller, M. Engelhard, K. Flügge, G. Pache, C. Philbrook, T. Vraetz, J. Finke, R. Mertelsmann, W. Lange (Freiburg, D)

2000

Current results in haploidentical stem cell transplantation in children

T.E. Klingebiel, P. Lang, M. Schumm, P. Bader, P.G. Schlegel, M. Eyrich, J. Greil, D. Niethammer, R. Handgretinger (Tübingen, Erlangen, D)

2001

Generation of allo-HLA restricted minor histocompatibility antigen HA-1 specific cytotoxic T-cells (CTLs) as tools for treatment of relapsed leukemia following HLA-mismatched stem cell transplantation

T. Mutis, E. Blokland, E. Schrama, E. Goulmy (Leiden, NL)

2002

Striking survival advantage of bad-risk acute myeloid leukaemia patients transplanted from haploidentical donors with KIR epitope incompatibility in the GVH direction

L. Ruggeri, M. Capanni, E. Urbani, A. Tosti, K. Perruccio, S. Posati, F. Aversa, A. Tabilio, M.F. Martelli, A. Velardi (Perugia, I)

2003

Differences in dendritic cell response to Aspergillus fumigatus as detected by gene expression profiling

H. Einsele, H. Hebart, C. Sinzger, S. Riegler, M. Bonin, J. Loeffler (Tübingen, D)

2004

NOD2/CARD15 mutations of recipients and donors associate with GvHD and TRM following allogeneic stem cell transplantation - results in 2 independent cohorts of patients

E. Holler, G. Rogler, J. Brenmoehl, A. Dickinson, G. Jackson, H. Greinix, G. Fischer, H. Herfarth, J. Hahn, G. Eissner, J. Schölmerich, R. Andreesen (Regensburg, D; Newcastle, UK; Vienna, A)

2005

Clinical trials of immuno-gene therapy using tumour mRNA transfected dendritic cells

G. Gaudernack, S. Aamdal, S. Dueland, J. Kyte, L. Mu, S. Saeboe-Larssen, M. Hauser, H. Waehre, G. Kvalheim (Oslo, N)

2006

Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups

T. de Witte, A. Hagemeijer, S. Suciu, A. Belhabri, M. Delforge, C. Aul, M. Aivado, D. Selleslag, H. Schouten, A. Ferrant, H. Biersack, S. Amadori, P. Muus, U. Jehn, F. Beeldens, J. Jansen, E. Hellstrom-Lindberg, T. Kovacsovics, U. Hess, P. Wijermans, G. Ossenkoppele, A. Gratwohl, J.-P. Marie, R. Willemze (Nijmegen, NL; Leuven, Brussels, B; Lyon, F; Duisburg, Düsseldorf, D; Brugge, B; Maastricht, NL; Essen, D; Rome, I; Munich, D; Stockholm, S; Lausanne, St. Gallen, CH; The Hague, Amsterdam, NL; Basel, CH; Paris, F; Leiden, NL)

Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease

O. Ringden, F. Frassoni, M. Uzunel, E. Lanino, B. Sundberg, H. Lonnies, G. Dini, A. Bacigalupo, F. Locatelli, W. Fibbe, K. Le Blanc (Stockholm, S; Genoa, I; Pavia, I; Leiden, NL)

2007

Single nucleotide polymorphisms of the NOD2/CARD15 gene are associated with significant increases in disease relapse and death in recipients of an unrelated donor haematopoietic stem cell transplant for acute leukaemia

N. Mayor, B. Shaw, D. Hughes, H. Maldonado-Torres, J.A. Madrigal, S. Keshav, S.G.E. Marsh (London, UK)

2008

Inhibitory KIR-ligand mismatching is associated with decreased incidence of relapse and improved disease-free survival after unrelated cord blood stem cell transplantation for patients with acute leukaemia

R. Willemze*, C. Arrais Rodrigues, M. Labopin, I. Ionescu, K. Boudjedir, G. Sanz, G. Michel, G. Socié, B. Rio, J. Garcia, G. Kögler, L. Lecchi, P. Loiseau, E. Gluckman, V. Rocha on behalf of Eurocord-Netcord* and Acute Leukaemia Working Party of the EBMT, Paris

2009

Prophylactic transfer of Bcr/Abl, PR1 and WT1-reactive donor T-cells after T-depleted allogeneic haematopoietic cell transplantation in patients with chronic myeloid leukaemia

M. Bornhäuser, C. Thiede, A. Kiani, U. Platzbecker, U. Oelschlägel, J. Radke, J. Schetelig, D. Lehmann, K. Hölig, G. Ehninger, M. Schmitz (Dresden, DE)

2010

Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study

S. Corbacioglu, S. Cesaro, M. Faraci, D. Valteau-Couanet, B. Gruhn, J. Boelens, C. Uderzo, N. Hewitt, A. Rovelli, J. Schrum, I. Müller, A. Schulz, J. Stein, R. Wynn, J. Greil, S. Matthes, K. Sykora, M. Albert, A. O'Meare, J. Massaro, R. D'Agostino, M. Pfitzenmaier, P. Sedlacek, P. Schlegel, J. Arvidson, J. Toporski, A. Groll, A. Fasth, J. Winiarski, H. Ozsahin, A. Schrauder, P. Bader, M. Hoyle, M. Iacobelli, G. Dini, C. Peters on behalf of the Pediatric Disease Working Party

2011

Engineered T-lymphocytes using a novel anti-leukaemia antigen, aurora-A kinase-specific T-cell receptor gene transfer successfully displayed anti-leukaemia reactivity

H. Fujiwara, K. Nagai, T. Ochi, J. An, T. Shirakata, J. Mineno, K. Kuzushima, H. Shiku, J. Melenhorst, E. Gostic, D. Price, M. Yasukawa (Toon, Ohtsu, Nagoya, Tsu, JP; Bethesda, US; Cardiff, UK)

2012

TCR gene editing results in effective immunotherapy of leukaemia without the development of GvHD

E. Provasi, P. Genovese, A. Lombardo, Z. Magnani, L. Pei-qi, A. Reik, V. Chu, D. Paschon, L. Zhang, J. Kuball, B. Camisa, A. Bondanza, G. Casorati, M. Ponzoni, F. Ciceri, C. Bordignon, P. Greenberg, M. Holmes, P. Gregory, L. Naldini, C. Bonini (Milan, IT, Richmond, Seattle, US)

2013

Long-term outcomes after autologous haematopoietic cell transplantation for multiple sclerosis: a joint study from the Center for International Blood and Marrow Research (CIBMTR) and the European Group for Blood and Marrow Transplantation

P. Muraro* (London, Great Britain), M. Pasquini, H. Atkins, J. Bowen, D. Farge, A. Fassas, M. Freedman, G. Georges, N. Hamerschlak, E. Havdrova, T. Kozak, G. Luigi Mancardi, D. Morais, R. Nash, S. Pavletic, J. Ouyang, A. Saiz, M. Badoglio, X. Zhong, M. P. Sormani, R. Saccardi

2014

T cells engineered with a chimeric antigen receptor (CAR) targeting Cd19 (Ctl019 cells) produce significant in vivo proliferation, complete responses and long-term persistence without Gvhd in children and adults with relapsed, refractory ALL

S. Grupp* (Philadelphia, United States), N. Frey, R. Aplenc, B. Levine, S. Maude, S. Rheingold, C. Strait Barker, D. Teachey, Y. Mahnke, D. Porter, C. June

2015

Improved cGvHD/relapse-free survival after HLA-identical sibling PBSC transplantation with ATG. A prospective multicenter randomized EBMT-labelled phase III trial (ATGfamilystudy)

C. Solano* (Valencia, Spain), F. Bonifazi, C. Wolschke, F. Patriarca, M. Pini, A. Nagler, M. Selleri, G. Messina, W. Bethge, P. Herrera Fuentes, R. Duarte, N. Cascavilla, M. Cimminiello, S. Guidi, J. Finke, A. Gallamini, C. Ferrà, J. Sierra, D. Russo, M. Petrini, G. Milone, F. Benedetti, M. Heinzelmann3, V. Liso, M. Jurado, E. M. Pogliani, F. Narni, A. Völp, G. Bandini, F. Ayuk, T. Ruutu, N. Kröger on behalf of Chronic Malignancies Working Party of the EBMT (CMWP)

2016

Multiple inhibitory receptors are expressed on central memory and memory stem T cells infiltrating the bone marrow of AML patients relapsing after allo-HSCT

Maddalena Noviello* (Milan, Italy), Francesco Manfredi, Tommaso Perini, Giacomo Oliveira, Filippo Cortesi, Cristina Toffalori, Valentina Gambacorta, Raffaella Greco, Jacopo Peccatori, Attilio Bondanza, Giulia Casorati, Paolo Dellabona, Nicoletta Cieri, Fabio Ciceri, Luca Vago, Chiara Bonini

2017

Impact of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of childhood ALL by FC and RQ-PCR: a retrospective study on behalf of COG, the PBMTC, the I-BFM the PDWP of the EBMT, and the Westhafen-Intercontinental-Group

Peter Bader* (Frankfurt, Germany), Emilia Salzmann-Manrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E. Woolfrey, Merav Bar, Michael R. Veneris, Michael J. Borowitz, Nirali Shah, Nathan Gossai, Peter Shaw, Allen Chen, Hermann Kreyenberg, Lucia Di Maio, Cornelia Eckert, Vincent van der Velden, Arjan Lankester, Thomas Klingebiel, Christina Peters, Stephan A. Grupp, Michael A. Pulsipher

2018

Non-myeloablative haematopoietic stem cell transplantation versus continued disease modifying therapies (DMT) in patients with highly active relapsing remitting multiple sclerosis (RRMS)

Richard K Burt* (Chicago, USA), Roumen Balabanov, John A Snowden, Basil Sharrack, Maria Carolina Oliveira, Flavia Nelson, Joachim Burman

2019

5–azacytidine (5-Aza) induction followed by allogeneic stem cell transplantation versus continuous 5-Aza in elderly MDS patients (55-70 years). A prospective randomized study (VidazaAllo Study)

Nicolaus Kröger, Katja Sockel, Christine Wolschke, Wolfgang Bethge, Richard F. Schlenk, Dominik Wolf, Michael Stadler, Guido Kobbe, Gerald Wulf, Gesine Bug, Kerstin Schäfer-Eckart, Christoph Scheid, Florian Nolte, Jan Krönke, Matthias Stelljes, Dietrich Beelen, Marion Heinzelmann, Detlef Haase, Hannes Buchner, Gabriele Blecker, Uwe Platzbecker* (Frankfurt, Germany)

2020

Results of the EBMT SAAWP Phase III Prospective Randomized Multicenter RACE Study of Horse ATG and Ciclosporin with or without Eltrombopag in naïve SAA patients

Régis Peffault de Latour* (Paris, France), Judith Marsh, Simona Iacobelli, Sofie Terwel, Anita Hill, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo Llamas, Beatrice Dresler, Jean Baptiste Mear, Maria Teresa Van Lint, Reinier A.P. Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H Russell, Louis Terriou, Anna Paola Iori, Isabel Sánchez- Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Austin Kulasekararaj, Serena Marotta, Talha Munir, Jennifer M.L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Alexander E Smith, Riley Cook, Luana Marano, Morag Griffin, Elena Palmisani, Petra Muus, Fabiana Cacace, Jakob R. Passweg, Gerard Socie, Ghulam J. Mufti, Carlo Dufour, Antonio Risitano

2021

Post-transplantation cyclophosphamide versus antithymocyte globulin after RIC regimen allo-HCT: first analysis of a prospective randomized multicenter trial in recipients of 10/10 matched donors

Eolia Brissot* (Paris, France), Hélène Labussière, Patrice Chevallier, Didier Blaise, Ibrahim Yakoub-Agha, Claude-Eric Bulabois, Anne Huynh, Sylvain Chantepie, Anne-Lise Menard, Marie-Thérèse Rubio, Patrice Ceballos, Mohamad Mohty

2022

Lisocabtagene maraleucel versus standard of care (salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation) as second-line therapy in relapsed/refractory lbcl: transform results

J. Abramson* (Boston, United States), M. Kamdar, S. R. Solomon, J. Arnason, P. B. Johnston, B. Glass, V. Bachanova, S. Ibrahimi, S. Mielke, P. Mutsaers, F. Hernandez-Ilizaliturri, K. Izutsu, F. Morschhauser, M. Lunning, D. G. Maloney, A. Crotta, S. Montheard, A. Previtali, L. Stepan, K. Ogasawara, T. Mack,

2023

Vedolizumab for prophylaxis of lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation from unrelated donors: a phase 3, randomized, double-blind, placebo-controlled, multicenter study

Yngvar Fløisand* (Oslo, Norway), Yi-Bin Chen, Mohamad Mohty, Robert Zeiser, Takanori Teshima, Yohei Takanami, Guillermo Rossiter, Johan Jansson,